Skip to main content
SpringerLink
Log in

The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: Evidence from clinical trials

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are among the most commonly prescribed and studied drugs in modern medicine. Their proven benefit in prevention of cardiovascular events is driven by their ability to markedly reduce low-density lipoprotein cholesterol (LDL-C). Recent analyses have provided insight into the relationship between statin-induced reductions in LDL-C and risk of rhabdomyolysis, liver toxicity, and cancer. Risk of statin-associated elevated liver enzymes and rhabdomyolysis is not related to the magnitude of LDL-C lowering. Instead, drug- and dose-specific effects of statins are more important determinants of liver and muscle toxicity than magnitude of LDL-C lowering. Furthermore, although there is an inverse association between LDL-C and cancer risk in both statin-treated and comparable control cohorts, statin therapy, despite significantly reducing LDL-C, is not associated with an increased risk of cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227–239.

    Article  PubMed  Google Scholar 

  2. Baigent C, Keech A, Kearney PM, et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267–1278.

    Article  PubMed  CAS  Google Scholar 

  3. Ridker PM, Cannon CP, Morrow D, et al.: C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352: 20–28.

    Article  PubMed  CAS  Google Scholar 

  4. Ridker PM, Morrow DA, Rose LM, et al.: Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 2005, 45: 1644–1648.

    Article  PubMed  CAS  Google Scholar 

  5. Corti R, Fuster V, Fayad ZA, et al.: Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 2005, 46: 106–112.

    Article  PubMed  CAS  Google Scholar 

  6. Robinson JG, Smith B, Maheshwari N, Schrott H: Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005, 46:1855–1862.

    Article  PubMed  CAS  Google Scholar 

  7. Staffa JA, Chang J, Green L: Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002, 346:539–540.

    Article  PubMed  Google Scholar 

  8. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH: The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 2005, 111:3051–3057.

    Article  PubMed  Google Scholar 

  9. Jacobs D, Blackburn H, Higgins M, et al.: Report of the Conference on Low Blood Cholesterol: mortality associations. Circulation 1992, 86: 1046–1060.

    PubMed  CAS  Google Scholar 

  10. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH: Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 2007, 50:409–418.

    Article  PubMed  CAS  Google Scholar 

  11. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al.: ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002, 106: 1024–1028.

    Article  PubMed  Google Scholar 

  12. Thompson PD, Clarkson P, Karas RH: Statin-associated myopathy. JAMA 2003, 289:1681–1690.

    Article  PubMed  CAS  Google Scholar 

  13. The SEARCH Collaborative Group: SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med 2008, 359:789–799.

    Article  Google Scholar 

  14. Newman TB, Hulley SB: Carcinogenicity of lipid-lowering drugs. JAMA 1996, 275:55–60.

    Article  PubMed  CAS  Google Scholar 

  15. Bjerre LM, LeLorier J: Do statins cause cancer? A metaanalysis of large randomized clinical trials. Am J Med 2001, 110:716–723.

    Article  PubMed  CAS  Google Scholar 

  16. Dale KM, Coleman CI, Henyan NN, et al.: Statins and cancer risk: a meta-analysis. JAMA 2006, 295: 74–80.

    Article  PubMed  CAS  Google Scholar 

  17. Alsheikh-Ali AA, Trikalinos TA, Kent DM, Karas RH: Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol 2008, 52:1141–1147.

    Article  PubMed  CAS  Google Scholar 

  18. Trikalinos TA, Ioannidis JP: Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient data. J Clin Epidemiol 2001, 54:245–252.

    Article  PubMed  CAS  Google Scholar 

  19. Mudd JO, Borlaug BA, Johnston PV, et al.: Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol 2007, 50: 1735–1741.

    Article  PubMed  CAS  Google Scholar 

  20. Demierre MF, Higgins PD, Gruber SB, et al.: Statins and cancer prevention. Nat Rev 2005, 5: 930–942.

    CAS  Google Scholar 

  21. Rossebo AB, Pedersen TR, Boman K, et al.: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359:1343–1356.

    Article  PubMed  Google Scholar 

  22. Peto R, Emberson J, Landray M, et al.: Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008, 359: 1357–1366.

    Article  PubMed  CAS  Google Scholar 

  23. Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495–1504.

    Article  PubMed  CAS  Google Scholar 

  24. Feinleib M: Summary of a workshop on cholesterol and noncardiovascular disease mortality. Prevent Med 1982, 11:360–367.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Box #63, 800 Washington Street, Boston, MA, 02111, USA

    Alawi A. Alsheikh-Ali

Authors
  1. Alawi A. Alsheikh-Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard H. Karas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alawi A. Alsheikh-Ali.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alsheikh-Ali, A.A., Karas, R.H. The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: Evidence from clinical trials. Curr Atheroscler Rep 11, 100–104 (2009). https://doi.org/10.1007/s11883-009-0016-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-009-0016-8

Keywords

Search

Navigation